

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE NINE MONTHS ENDED 31 MARCH 2023

THE GROUP				
	Unaudited Quarter Ended 31 Mar 2023	Unaudited Quarter Ended 31 Mar 2022	Unaudited 9 Months Ended 31 Mar 2023	Unaudited 9 Months Ended 31 Mar 2022
	Rs'000	Rs'000	Rs'000	Rs'000
Turnover	784,410	791,256	2,239,823	2,259,920
Earnings Before Interests, Taxation, Depreciation and Amortisation (EBITDA)	158,322	183,100	464,378	546,317
Depreciation and amortisation	(44,748)	(36,170)	(125,762)	(101,033)
Earnings Before Interests and Taxation (EBIT)	113,574	146,930	338,616	445,284
Net finance cost	(15,593)	(14,189)	(44,044)	(44,009)
Profit before taxation	97,981	132,741	294,572	401,275
Taxation	(16,530)	(22,456)	(49,494)	(69,316)
Profit after tax	81,451	110,285	245,078	331,959
Attributable to:				
Equity holders	81,451	110,285	245,078	331,959
Earnings per share				
Earnings attributable to equity holders	81,451	110,285	245,078	331,959
Number of shares in issue ('000)	569,941	569,941	569,941	569,941
Earnings per share (Rs/Cs)	0.14	0.19	0.43	0.58

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 31 MARCH 2023

THE GROUP		
	Unaudited As at 31 Mar 2023	Audited As at 30 June 2022
	Rs'000	Rs'000
ASSETS		
Non-current assets	2,616,124	2,453,081
Current assets	865,587	843,057
TOTAL ASSETS	3,481,711	3,296,138
EQUITY AND LIABILITIES		
Equity attributable to:		
Equity holders	1,306,600	1,061,522
TOTAL EQUITY	1,306,600	1,061,522
Non-current liabilities	1,304,956	1,250,959
Current liabilities	870,155	983,657
TOTAL EQUITY AND LIABILITIES	3,481,711	3,296,138

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY AS AT 31 MARCH 2023

Attributable to equity holders				
	Issued Capital	Revaluation reserve	Retained Earnings	Total Equity
	Rs'000	Rs'000	Rs'000	Rs'000
At 1 July 2021	289,801	265,494	269,900	825,195
Profit for the period	-	-	331,959	331,959
At 31 March 2022	289,801	265,494	601,859	1,157,154
At 1 July 2022	289,801	345,241	426,480	1,061,522
Profit for the period	-	-	245,078	245,078
At 31 March 2023	289,801	345,241	671,558	1,306,600

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED 31 MARCH 2023

THE GROUP		
	Unaudited 9 Months Ended 31 Mar 2023	Unaudited 9 Months Ended 31 Mar 2022
	Rs'000	Rs'000
Net Cash flows from operating activities	304,299	424,581
Net Cash flows used in investing activities	(234,875)	(97,806)
Net Cash flows used in financing activities	(239,406)	(160,607)
(Decrease)/Increase in cash and cash equivalent	(169,982)	166,168
MOVEMENT IN CASH AND CASH EQUIVALENT		
At the beginning of the period	398,220	234,852
Movement during the period	(169,982)	166,168
At the end of the period	228,238	401,020

NOTES

The abridged financial statements for the 9 months ended 31 March 2023 are unaudited and have been prepared using the same accounting policies as in the audited financial statements for the year ended 30 June 2022.

The above results are a consolidated view of the operations of C-Care Darné, C-Care Wellkin and C-Lab including C-Care North Ltd and Centre de Radiothérapie de l'Océan Indien Ltd, wholly owned subsidiaries of C-Care (Mauritius) Ltd (the "Group").

The Group has seen an increase in its normal activities and maintained a good performance despite the decrease in covid related activities and increase in operating costs compared to same period last year.

The Board of Directors of C-Care (Mauritius) Ltd accepts full responsibility for the accuracy of the information contained in this report.

By Order of the Board

CIEL Corporate Services Ltd
Company Secretary

Date: 9 May 2023

BRN: C07002054

This report is pursuant to Rule 17 of the Development & Enterprise Market and Securities Act 2005.

Copies of the Unaudited Condensed Financial Statements are available to the public free of charge at the Company's registered office: 5th Floor, Ebène Skies, rue de l'Institut, Ebène. The statement of direct and indirect interests of insiders pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007 is available free of charge at the registered office of the Company.